Helicobacter pylori infection
Conditions
Interventions
Group A:Esomeprazole 20 mg bid, doxycycline 0.1 g bid, metronidazole 0.4 g tid, potassium bismuth citrate 220 mg bid, treatment course 14 days.
Group B:Venlafaxine 20mg twice daily, Doxycycline 0.1g twice daily, Metronidazole 0.4g three times daily, Potassium Citrate 220mg twice daily for a course of 14 days.
Group C:Esomeprazole 20 mg bid, Clarithromycin 0.5g bid, Metronidazole 0.4g tid, Potassium bismuth citrate 220mg bid, treatment course 14 days.
Sponsors
Tianjin Fourth Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Positive Hp infection confirmed by 13C or 14Cbreath test 2. Age 18-70 years; 3. Positive penicillin skin test 4. Previous allergy history to penicillin or amoxicillin. 5. Initial treatment of patients
Exclusion criteria
Exclusion criteria: 1. Those who have used antibiotics, bismuth agents or non-steroidal anti-inflammatory drugs within one month; those who have used acid inhibitors within two weeks before HP eradication therapy; 2. Active peptic ulcer, accompanied by complications such as bleeding, perforation, obstruction and canceration; 3. History of esophageal or gastrectomy surgery; 4. Suffering from serious underlying diseases (heart, lungs, brain, liver, kidneys, etc.), suffering from malignant tumors or other diseases; 5. Pregnant or lactating women; 6. Participate in other research within three months and be unable to express one's own ideas correctly or cooperate with the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of adverse events;Economic benefit; | — |
Countries
China
Contacts
Public ContactZhang Qiuzan
Tianjin Fourth Central Hospital
Outcome results
None listed